Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...
Watch this webinar where we address one of the main challenges in bringing AAV-based therapies to patients, is the ability to efficiently translate bench-scale processes to commercial GMP manufacturing while meeting the high dosage requirements. Our Experts from Polyplus, Exothera and Alexion collaborated for the development of a highly scalable AAV manufacturing platform with a capacity ranging from 1L to 200L and 2000L.
Key Learning Objectives:
- Developing scalable transfection process with DOE (Design of Experiments)
- Scaling-up while maintaining consistent transfection complex growth for efficient delivery to cells